Table 2.
Event Incidence and Hazard Ratios with 95% Confidence Intervals for IPTW Analysis of the Rivaroxaban and Warfarin Cohorts Using an Intent-To-Treat Approach
| Rivaroxaban N = 2097 n (%) |
Warfarin N = 2842 n (%) |
HR (95%CI) | |
|---|---|---|---|
| 3-Month | |||
| Composite of recurrent venous thromboembolism or major bleeding | 96 (4.58) | 130 (4.57) | 1.08 (0.82–1.42) |
| Recurrent venous thromboembolism | 74 (3.53) | 96 (3.38) | 1.07 (0.78–1.46) |
| Major bleeding | 27 (1.29) | 40 (1.41) | 1.19 (0.72–1.97) |
| Intracranial hemorrhage | 2 (0.10) | 5 (0.18) | 0.66 (0.12–3.59) |
| Gastrointestinal bleeding | 17 (0.81) | 24 (0.84) | 1.16 (0.61–2.21) |
| Genitourinary bleeding | 4 (0.19) | 6 (0.21) | 1.08 (0.30–3.93) |
| 6-Month | |||
| Composite of recurrent venous thromboembolism or major bleeding | 105 (5.01) | 166 (5.84) | 0.96 (0.75–1.24) |
| Recurrent venous thromboembolism | 81 (3.86) | 115 (4.05) | 1.01 (0.76–1.36) |
| Major bleeding | 30 (1.43) | 59 (2.08) | 0.93 (0.59–1.47) |
| Intracranial hemorrhage | 2 (0.10) | 7 (0.25) | 0.50 (0.10–2.50) |
| Gastrointestinal bleeding | 18 (0.86) | 37 (1.30) | 0.84 (0.47–1.51) |
| Genitourinary bleeding | 4 (0.19) | 9 (0.32) | 0.80 (0.24–2.63) |
| 12-Month | |||
| Composite of recurrent venous thromboembolism or major bleeding | 122 (5.82) | 208 (7.32) | 0.93 (0.74–1.16) |
| Recurrent venous thromboembolism | 89 (4.24) | 140 (4.93) | 0.95 (0.72–1.2) |
| Major bleeding | 39 (1.86) | 80 (2.81) | 0.92 (0.62–1.36) |
| Intracranial hemorrhage | 5 (0.24) | 13 (0.46) | 0.76 (0.27–2.19) |
| Gastrointestinal bleeding | 21 (1.00) | 47 (1.65) | 0.80 (0.47–1.37) |
| Genitourinary bleeding | 5 (0.24) | 10 (0.35) | 0.88 (0.29–2.63) |
CI Confidence interval, HR Hazard ratio, N Number